Sheryl M. Gough

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 110 citations

Life Sciences, Biochemistry, Endocrinology +15

Age-related epigenetic drift in the pathogenesis of MDS and AML

Shinji Maegawa, Sheryl M. Gough, Naoko Watanabe‐Okochi et al. · Genome Research · 2014 · 86 citations · Full text

Medicine, Genetics, Hematology +16

NUP98–PHF23 Is a Chromatin-Modifying Oncoprotein That Causes a Wide Array of Leukemias Sensitive to Inhibition of PHD Histone Reader Function

Sheryl M. Gough, Fan Lee, Fan Yang et al. · Cancer Discovery · 2014 · 84 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome

Yang Jo Chung, Carine Robert, Sheryl M. Gough et al. · Leukemia Research · 2013 · 55 citations

Life Sciences, Genetics, Molecular Biology +11